Download PDF
Thromb Haemost 2004; 92(03): 666-667
DOI: 10.1055/s-0037-1613738
Case Report
Schattauer GmbH

A case of acquired von Willebrand syndrome successfully treated with recombinant Factor VIIa during thyroidectomy

Agnes Smaradottir
1   University of Connecticut Health Center, Connecticut, USA
,
Robert Bona
1   University of Connecticut Health Center, Connecticut, USA
› Author Affiliations
Further Information

Publication History

Received 06 April 2004

Accepted after revision 20 June 2004

Publication Date:
15 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Veyradier A, Jenkins SPC, Resinous E. et al. Acquired von Willebrand syndrome: From pathophysiology to management. Thromb Haemost 2000; 84: 175-82.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Budde U, Bergmann F, Michiels JJ. Acquired von Willebrand syndrome. Experience from 2 years in a single laboratory compared with data from the literature and an International Registry. Semin Thromb Hemost 2002; 28: 227-37.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Budde U. et al. Subunit Composition of plasma von Willebrand factor in patients with the mye-loproliferative syndrome. Blood 1986; 68: 1213-7.
    PubMedGoogle Scholar
  • 4 Federica AB, Rand JH, Bucciarelli P. et al. Acquired von Willebrand syndrome. Data from an International Registry. Thromb Haemost 2000; 84: 345-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Zimmerman TS. et al. Determination of the von Willebrand disease antigen in plasma by quantitative immuno-electrophoresis. J Lab Clin Med 1975; 86: 152-9.
    PubMedGoogle Scholar
  • 6 Ruggeri ZM, Zimmerman T. Variant von Willebrand disease. J Clin Invest 1980; 65: 1318-25.
    CrossrefPubMedGoogle Scholar
  • 7 Montgomery RR, Zimmerman TS. Von Willebrand’s Disease antigen II. J Clin Invest 1978; 61: 1498-1507.
    CrossrefPubMedGoogle Scholar
  • 8 Simone JV, Vanderheiden J, Abildgaard CF. A semiautomatic one-stage Factor VIII assay with a commercial prepared standard. J Lab Clin Med 1967; 69: 706-12.
    PubMedGoogle Scholar
  • 9 Shapiro AD, Gilchirst GS, Hoots WK. et al. Prospective, randomised trial of two doses of rFVIIa (Novoseven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand’s Syndrome: A single institution experience. Am J Hematol 2003; 72: 243-7.
    CrossrefPubMedGoogle Scholar
  • 11 Federici AB, Stabile F, Castaman G. et al. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998; 92: 2707-11.
    PubMedGoogle Scholar
  • 12 Bussel JB. Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: Review of the literature. Vox Sang 1987; 52: 206-11.
    CrossrefPubMedGoogle Scholar
  • 13 Friederich PW, Philip FW, Wever PC. et al. Successful treatment with recombinant Factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand Disease. Am J Hematol 2001; 66: 292-4.
    CrossrefPubMedGoogle Scholar
  • 14 Hoffmann M, Monroe III DM. The action of high dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol 2001; 38: 6-9.
    PubMedGoogle Scholar